NCT04692181: SYN-004 Safety and Tolerability in Allo-HCT Subjects |
|
|
| Recruiting | 1b/2a | 36 | US | SYN-004, Ribaxamase or Placebo | Theriva Biologics, Inc., Washington University School of Medicine | 121121000119106, Acute Graft-versus-host Reaction Following Bone Marrow Transplant (Disorder) | 12/24 | 12/25 | | |
